Recludix Pharma, a leader in the discovery of inhibitors for challenging targets in inflammatory disease, today announced a ...

PRESS RELEASE AB SCIENCE ANNOUNCES THE SETTLEMENT DELIVERY OF ITS LATEST CAPITAL INCREASE FOR €1.8 MILLION Paris, May 23, 2025, 8am CET AB Science S.A. (the “Company” or “AB Science”, Euronext – ...

DelveInsight’s Peritoneal Cancer Pipeline report depicts a robust space with 55+ active players working to develop 60+ ...

Preclinical data has showing compelling findings for HT-KIT among patients with rare and aggressive KIT-driven cancers, ...

PRESS RELEASEMASITINIB SHOWS PROMISING NEUROPROTECTIVE EFFECTS IN NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE MODEL A NEW PUBLICATION IN THE SCIENTIFIC JOURNALPLOS ONE,SHOWS THAT MASITINIB CAN LOWER ...

The recent results of tolebrutinib in non-active secondary progressive MS presented at the ECTRIMS 2024 conference, reinforce the scientific hypothesis that targeting microglia in nSPMS is a valid ...

The story of chronic itch and its impact on quality of life is one dermatologists have heard often. Until recently, treatment ...

Drugmakers are turning to biomarkers, like folate receptor alpha, and even cell therapies to tackle this deadly cancer in new ...

The innate immune system: Components of the innate immune system are being recognized to play a role in MS. Masitinib is a mast cell inhibitor currently being studied. LINGO-1, Notch and Wnt have ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...